Dylan Brodeur testified that he operated an Ethereum node in New York from 2021 to 2023. Federal prosecutors used his testimony to argue that a $50 million crypto theft case should be tried in the Southern District of New York. Investigators linked Brodeur to the node by matching IP data from an Etherscan account with Verizon network records. This testimony supports venue jurisdiction in the ongoing legal proceedings involving significant crypto theft.
Ethereum node operator testimony in a $50 million crypto theft case provides context for readers. For those following cryptocurrency markets, here is Pluang's market snapshot as of Oct 19, 2026 19:21 WIB: out of 50 major cryptocurrencies priced on Pluang, 23 rose and 25 fell. Notable movers include FTM (Fantom) at Rp11.382 with a -2.05% change, CAKE (PancakeSwap) at Rp38.748 with 87% sell order activity, and ENJ (Enjin Coin) at Rp486 with 95% sell order activity. ENJ's 95% sell order activity stands out as the most notable figure.
Nyxoah announced preliminary Q3 2026 revenue of €9.2 million, up 19% sequentially, driven by a 29% increase in U.S. sales. The company submitted a PMA supplement to the FDA to expand its Genio device indication for patients with complete concentric c...
ASML Holding N.V. announced recent transactions under its ongoing share buyback program, repurchasing a total of 233,867 shares between October 12 and October 16, 2026. The shares were bought back at weighted average prices ranging from €1,444.83 to ...
The Phase 3 ALKIVIA trial demonstrated that efgartigimod significantly improves symptoms in patients with autoimmune myositis, including immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM). Patients showed meaningful clinical improve...
In 2025, Berkshire Hathaway, led by Greg Abel, received $479 million in dividends from its $1.3 billion investment in American Express. This highlights the value of holding strong dividend-paying stocks for steady income. Retail investors can apply s...
Lexeo Therapeutics announced an educational event on October 21, 2026, focusing on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The event will feature discussions by Lexeo's Chief Medical Officer and a lea...
